Urolog. pro Praxi, 2008; 9(6): 309-312

PSA-velocita a její význam pro včasnou diagnostiku ca prostaty

MUDr. Martin Hrabec, doc. MUDr. Vladimír Študent Ph.D, MUDr. Michal Grepl, et al
Urologická klinika FN a LF UP v Olomouci

Cílem práce je posoudit význam velocity PSA (PSAV) při diagnostice karcinomu prostaty. V období od června 2006 do září 2007 jsme provedli 436 biopsií prostaty u pacientů s klinickým podezřením na karcinom prostaty. U 214 z nich bylo možno hodnotit velocitu PSA a posoudit její souvislost s histologickým průkazem prostatitidy, BPH a adenokarcinomu prostaty. Průměrná hodnota PSA velocity u pacientů s histologicky prokázanou BPH byla 2,38 ng/ml/rok a s prokázaným adenokarcinomem prostaty 3,70 ng/ml/rok. PSAV u chronické prostatitidy byla 3,70 ng/ml/rok, PSA velocita však nemá u chronického zánětlivého onemocnění prostaty žádný prognostický význam. Jedná se o významný pomocný faktor při stanovení rizika diagnózy karcinomu prostaty. Je třeba ji ale posuzovat v souvislosti s absolutní hodnotou PSA.

Keywords: PSA, karcinom prostaty, biopsie prostaty

Published: January 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hrabec M, Študent V, Grepl M, al E. PSA-velocita a její význam pro včasnou diagnostiku ca prostaty. Urol. praxi. 2008;9(6):309-312.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Carter HB, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992; 267(16): 2215-2220. Go to original source...
    2. Carter HB, et al. Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity. Urology 1995; 45(4): 591-596. Go to original source... Go to PubMed...
    3. Connoly D, et al. Methods of calculating prostate-specific antigen velocity. Eur Urol 2007; 52: 1044-1051. Go to original source... Go to PubMed...
    4. Etzioni RD, et al. Is prostate-specific antigen velocity useful in early detection of prostate cancer? A critical appraisal of the evidence. J Natl Cancer Inst 2007; 99(20): 1510-1515. Go to original source... Go to PubMed...
    5. Ito K, et al. Usefulness of prostate-specific antigen velocity in screening for prostate cancer. Int J Urol 2002; 9(6): 316-321. Go to original source... Go to PubMed...
    6. Loeb S, et al. Prostate specific antigen velocity threshold for predicting prostate cancer in young men. J Urol 2007; 177(3): 899-902. Go to original source... Go to PubMed...
    7. Loeb S, et al. Prostate specific antigen velocity in men with total prostate specific antigen less than 4 ng/ml. J Urol 2007; 178(6): 2348-2352. Go to original source... Go to PubMed...
    8. Moul JW, et al. Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening. J Urol 2007; 177(2): 499-503. Go to original source... Go to PubMed...
    9. Schröder FH, et al. Does PSA velocity predict prostate cancer in pre-screened populations? Eur Urol 2006; 49(3): 460-465. Go to original source... Go to PubMed...
    10. Sun L, et al. Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged < 50 years. BJU Int 2007; 99: 753-757. Go to original source... Go to PubMed...
    11. Študent V, Fiala R. První výsledky studie Kapros v Olomouckém kraji. Čes Urol 2006; 1: 19-22.
    12. Ulmert D, et al. Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population. J Clin Oncol 2008; 26(6): 835-841. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.